Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05568719 · ClinicalTrials.gov registry record · Phase 3
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
A Phase 3 study of Hemophilia A and Hemophilia B, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 173
- Enrollment target
- 16
- Study locations
NCT05568719 is a Phase 3 study of Hemophilia A and Hemophilia B that is actively recruiting participants, run by Pfizer. The registered enrollment target is 173 participants, above the 87-participant average among 42 other Hemophilia A trials with a reported enrollment target (99% higher). The trial reports 16 study locations across 8 states.
The verdict
NCT05568719, a Phase 3 study of Hemophilia A and Hemophilia B, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 173 participants
- Enrollment target
- 16
- Study locations
Study Summary
A study to learn about the long-term safety and efficacy of giroctocogene fitelparvovec or fidanacogene elaparvovec in patients with hemophilia A or hemophilia B respectively, who have received treatment through prior participation in a Pfizer-sponsored clinical trial. Data collection and participant visits will be based on standard of care.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Testing of hepatic AAV Vector integration
Study Locations (16)
California
- The Regents of the University of California||UC Davis Health - Rancho Cordova
- UC Davis Health - Sacramento
- UC Davis Ambulatory Care Clinic - Sacramento
- UC Davis Hemophilia Treatment Center - Sacramento
- UC Davis Medical Center - Sacramento
- UCSF Outpatient Hematology Clinic - San Francisco
Florida
- USF Health Morsani Center For Advanced Healthcare - Tampa
- The University of South Florida Board of Trustees - Tampa
New York
- Cornell University||Joan & Sanford I. Weill Medical College - New York
- Weill Cornell Medical College-New York Presbyterian Hospital - New York
New South Wales
- Royal Prince Alfred Hospital - Camperdown
- Sydney Local Health District (RPAH Zone) - Camperdown
Mississippi
- Mississippi Center For Advanced Medicine - Madison
Pennsylvania
- The Childrens Hospital of Philadelphia Division of Hematology - Philadelphia
Washington
- Washington Institute for Coagulation - Seattle
İ̇zmir
- Ege Universitesi Hastanesi - Izmir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 173 participants |
| Start Date | 2022-12-28 |
| Est. Completion | 2040-02-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05568719
The ClinicalTrials.gov registry entry for NCT05568719 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 173 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 87-participant average among 42 other Hemophilia A trials with a reported enrollment target (99% higher). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hemophilia A appearing as the primary indexed condition, and to 1 intervention - of which Testing of hepatic AAV Vector integration is the first listed.
NCT05568719 reports 16 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT05568719 about?
NCT05568719 is a clinical study titled "Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively". A study to learn about the long-term safety and efficacy of giroctocogene fitelparvovec or fidanacogene elaparvovec in patients with hemophilia A or hemophilia B respectively, who have received treatment through prior participation in a Pfizer-sponsored clinical trial. Data collection and participan...
What is the current status of trial NCT05568719?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 173 participants. The study started on 2022-12-28. Estimated completion is 2040-02-25.
What conditions does trial NCT05568719 study?
This clinical trial studies the following conditions: Hemophilia A, Hemophilia B.
What interventions are being tested in trial NCT05568719?
The interventions under investigation include: Testing of hepatic AAV Vector integration (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05568719?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05568719 being conducted?
This trial has 16 study locations across California, Florida, Mississippi, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemophilia A
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
RECRUITING · Phase 3
-
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
RECRUITING · Phase 3
-
SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis
RECRUITING · Phase 3
-
Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A
ACTIVE NOT RECRUITING · Phase 3
-
Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.